{
    "symbol": "ARWR",
    "quarter": 2,
    "year": 2022,
    "date": "2022-05-10 21:57:07",
    "content": " We just started opening clinical sites and enrolling GATEWAY a few weeks ago, so we don't have a great visibility into how long it may take to accrue all 16 patients, however, is to have the study fully enrolled or at least have a meaningful amount of patient enrolled by the end of this year. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. And while we are doing larger studies, we do believe that that, that a large outcome study would be interesting for ANG3, given what we've seen so far in the Phase 1study, and so that's our expectation at this point to go after the large dyslipidemia population with that, that that drug. Your line is open. Your line is open."
}